Marcia Clark Table of Contents
Article information
SAN DIEGO, Sept. 08, 2023 (World NEWSWIRE) — Organovo Holdings, Inc. (Nasdaq: ONVO) (Organovo), a clinical phase biotechnology company that is focused on building novel human therapies with significant fidelity in a few-dimensional (3D) human tissues that recapitulate crucial features of human ailment, right now introduced that Keith Murphy, Founder and Government Chairman, will present a company update and maintain conferences with institutional buyers throughout the H.C. Wainwright 25th Annual World wide Investment Meeting getting held September 11-13, 2023.
Report content material
Institutional investors interested in arranging a meeting with administration can register to go to the convention virtually or in-particular person at the Lotte New York Palace Lodge.
Write-up material
Date: September 11, 2023
Presentation Time: 10:00 a.m. ET
Presenter: Keith Murphy
About Organovo
Organovo is a clinical stage biotechnology organization that is producing medication that are demonstrated to be efficient in 3-dimensional (3D) human tissues as candidates for drug growth. The company’s lead molecule, FXR314, is on the route for Section 2 investigation in inflammatory bowel disease and has possible software in metabolic ailment and oncology. The enterprise has proprietary engineering applied to develop 3D human tissues that mimic critical features of indigenous human tissue composition, architecture, perform and illness. For much more info visit Organovo’s web-site at www.organovo.com.
Ahead-Searching Statements
Any statements contained in this push launch that do not describe historical facts represent ahead-looking statements as that term is described in the Private Securities Litigation Reform Act of 1995. Any ahead-searching statements contained herein are based mostly on present anticipations, but are matter to a quantity of hazards and uncertainties. These dangers and uncertainties and other factors are determined and explained in more element in the Company’s filings with the SEC, together with its Yearly Report on Form 10-K submitted with the SEC on July 14, 2023, as these possibility things are updated in its most just lately submitted Quarterly Report on Kind 10-Q filed with the SEC on August 10, 2023. You should not spot undue reliance on these forward-searching statements, which talk only as of the date that they were being made. These cautionary statements need to be regarded as with any composed or oral ahead-wanting statements that the Company may well concern in the potential. Except as required by applicable law, like the securities legislation of the United States, the Company does not intend to update any of the ahead-wanting statements to conform these statements to mirror genuine final results, later on activities or circumstances or to replicate the occurrence of unanticipated events.
Trader Call
Amato and Partners, LLC
Trader Relations Counsel
[email protected]
